The exploration of privileged structures in drug discovery is a rapidly emerging theme in medicinal chemistry. These structures represent a class of molecules capable of binding to multiple receptors with high affinity.1,2 The exploitation of these molecules should allow the medicinal chemist to rapidly discover biologically active compounds across a broad range of therapeutic areas on a reasonable time scale.